Savient Pharmaceuticals appoints president of Savient Europe

David Veitch takes up the role

David Veitch took over as president of Savient Europe yesterday.

Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management to the US biopharmaceutical firm. He will be responsible for establishing, building and leading Savient's European regional organisation to launch and drive the future growth of Krystexxa (pegloticase), a drug for the treatment of chronic gout in adult patients refractory to conventional therapy.

Savient submitted its European Marketing Authorisation Application (MAA) for Krystexxa in May 2011, and anticipates EU approval in the second half of 2012.

Veitch joins Savient with more than 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and immunology.

Most recently he was senior vice president of European marketing and brand commercialisation at Bristol Myers Squibb.

Prior to that, Veitch spent 10 years in a number of leadership positions at Bristol-Myers Squibb.

You may also like

Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Distribution

Tower Cold Chain launches live tracking and monitoring for pharmaceutical distribution

The upgrade allows customers to access real-time insights into shipments, facilitating the optimisation of cold chain processes
Manufacturing

Europe’s generic medicines are disappearing, study finds

Over a ten year period, the number of generic medicines withdrawn from the market increased by 12%
Pharmaceutical

Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024

Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Subscribe now